The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Jun. 23, 2020

Filed:

Apr. 08, 2016
Applicant:

Biogen Chesapeake Llc, Cambridge, MA (US);

Inventors:

Sven Jacobson, New York, NY (US);

Gillian Clarke, Middlesex, GB;

Rajinder Matharu, Bloomington, IN (US);

Assignee:

Biogen Chesapeake LLC, Cambridge, MA (US);

Attorney:
Primary Examiner:
Assistant Examiner:
Int. Cl.
CPC ...
A61K 31/64 (2006.01); A61K 47/18 (2017.01); A61K 9/08 (2006.01); A61K 47/26 (2006.01); A61K 47/10 (2017.01); A61K 9/00 (2006.01);
U.S. Cl.
CPC ...
A61K 31/64 (2013.01); A61K 9/0019 (2013.01); A61K 9/08 (2013.01); A61K 47/10 (2013.01); A61K 47/18 (2013.01); A61K 47/26 (2013.01);
Abstract

The invention provides liquid formulations of compounds that act at sulfonylurea receptors that are suitable for intravenous and intra-arterial infusion. Compounds active at a sulfonylurea receptor include glibenclamide, tolbutamide, repaglinide, nateglinide, meglitinide, midaglizole, LY397364, LY389382, glyclazide, and glimepiride. Liquid formulations may be concentrated solutions suitable for storage; may be diluted (e.g., dilution of 1:1 or 1:1.2) suitable for bolus injections, and may be further diluted (e.g., dilution of 1:10 or 1:20 or more) for intravenous and intra-arterial infusion over an extended period of time. For example, a liquid formulation may include at least about 0.05 mg/ml glibenclamide in a water-based solution including 40% polyethylene glycol 300, 10% Ethanol, 50% water, at about pH 9. The solution may include a buffer, and is suitable for storage in refrigerator or at room temperature. This solution may be diluted 1:1, or more (e.g., 1:20) without precipitation of the glibenclamide.


Find Patent Forward Citations

Loading…